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Abstract
 .Stably transfected Balb-C 3T3 fibroblasts clone 5 , overexpressing a catalytically active tissue transglutaminase, showed
 .a basal adenylate cyclase activity lower than control cells clone 1 . Several modulators of the adenylate cyclase activity
 2q .forskolin, Mn and pertussis toxin showed the existence of a marked negative control on the adenylate cyclase activity
present in clone 5 cells. Very interestingly, this same marked negative control was also found in a Balb-C 3T3 fibroblast
 .clone stably transfected with a mutagenized human tissue transglutaminase mut277 cys ) ser virtually devoid of
 .transglutaminase catalytic activity clone Ser . Conversely, a significant increase of the adenylate cyclase activity was
observed in bovine aortic endothelial cells after the lowering of tissue transglutaminase expression levels by the transfection
of an eukaryotic expression vector containing the gene for tissue transglutaminase in antisense orientation. All these
findings suggest a possible role for type II tissue transglutaminase as a negative modulator of the adenylate cyclase activity
in different cell types, beside its transglutaminase enzyme activity.
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1. Introduction
G-proteins are a large family of proteins, able to
bind GTP and hydrolyze it to GDP by virtue of an
w xintrinsic GTPase activity 1 . Upon dissociation of
GDP, they bind a new molecule of GTP and under-
take a new cycle: therefore they switch between a
GTP-bound and a GDP-bound state. In the GTP-
bound state, G-proteins actively interact with cellular
enzymes modulating their activity. These proteins
)  .Corresponding author. Fax: 39-81 566-5863.
play a central role in regulating the metabolic path-
ways through which external signals affect important
w xcell metabolic processes 2 . Beside the classical het-
 .erotrimeric G-proteins and the small G-proteins p21
w x3,4 , a growing number of proteins, some of them
already known for peculiar catalytic activities, are
w xbeing shown to possess G-proteins properties 5–9 .
The role of these novel G-proteins on signaling
metabolic pathways is largely uncharacterized. Re-
 . cently, tissue transglutaminase type II, tTGase EC
. 2q2.3.2.13 , a Ca -dependent enzyme that catalyzes
the post-translational modification of proteins through
the formation of isopeptide bonds between glutamine
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w xand lysine residues 10–12 , has been identified as a
new G-protein since it both binds GTP and has
w xGTPase activity 5–8 . Moreover, it has been shown
to couple agonist-activated a -adrenergic receptors to1
w xmembrane-bound phospholipase C activity 13,14 .
To assess a possible role for this enzyme in the
adenylate cyclase signal transducting pathway, we
have expressed the wild type and active-site mutage-
nized tissue transglutaminase genes in a cell model
which is virtually devoid of such enzyme. We have
observed that in both cell clones clone 5 and clone
.Ser an inhibitory control of adenylate cyclase activ-
ity parallels the overexpression of the tissue transglu-
taminase in the transfected cells. Moreover, the low-
ering of the tissue transglutaminase expression in
 .bovine aortic endothelial BAE cells by the transfec-
tion of an expression vector, carrying the cDNA
sequence of the tTGase gene in antisense orientation,
is associated with a significant increase of the adeny-
late cyclase activity present in these cells. These two
different and complementary results strongly suggest
that tTGase may play a critical role as adenylate
cyclase modulator in different cell types.
2. Materials and methods
2.1. Materials
The following materials were obtained from the
w 32 x  .indicated sources: a- P ATP 29.6 TBqrmmol ,
w 32 x  .g- P GTP 222 TBqrmmol , antibodies anti-Ga i
 .and -Ga subunits ASr7 and RMr1 rabbit antiseras
from Du Pont-New England Nuclear, UK. Pertussis
 .toxin PT was obtained from Sigma Chemicals, St.
Louis, MO, USA. The sources of all other materials
are described where required.
2.2. Cell culture and transfections
 .  .Control clone 1 and tTGase-transfected clone 5
Balb-C 3T3 fibroblasts were obtained and grown as
w xpreviously reported by Gentile et al. 15 . Active
site-mutagenized tissue transglutaminase gene was
w xobtained as previously described 16 . Balb-C 3T3
fibroblast clone Ser was obtained by following a
transfection and selection procedure previously re-
w xported by Gentile et al. 15 . Bovine aortic endothe-
 .lial BAE cells were obtained from Dr G. Persico
 .I.I.G.B., C.N.R., Naples, Italy and grown as re-
w xported by Nara et al. 17 . BAE cells were transiently
transfected by a pSG5 eukariotic expression vector
containing the cDNA to the human tissue transglu-
 . w xtaminase sequence pSG5-tTGase-AS 18 or by
 .pSG5 alone control vector by using a lipofection
technique Lipofectin, Gibco BRL, Life Technolo-
.gies . After three passages, the cells were then used
for the enzymatic assays.
2.3. a ADP-ribosylation in ˝i˝oi
This assay was carried out according to Kopf and
w xWoolkalis 19 by using confluent monolayer cells
and 10 ng of PT per ml of culture medium. After 18
h, the cells were used for membrane preparation to
evaluate their adenylate cyclase activity.
2.4. Membrane preparation
 .Confluent cells 80% were scraped, washed three
times in PBS 150 mM NaCl, 20 mM KCl, 10 mM
.Na HPO , 15 mM KH PO , pH 7.4 and the final2 4 2 4
pellet suspended in a sucrose saline buffer 0.33 M
sucrose; 20 mM Tris-HCl pH 7.5, 2 mM EDTA, 0.5
.mM EGTA, 2 mM PhMeSO F, 5 mgrml leupeptin2
at a final concentration of 4–6=106 cellsrml. Three
ml aliquots of cell suspension were homogenized
with a loose-fitting glass-glass Dounce homogenizer
 .30 strokes . The membrane pellet, obtained by cen-
trifugation of the homogenate at 27 000=g for 20
min at 48C, was resuspended in the specific buffer
required in the different types of assays while the
supernatant was used as cytosolic enzymatic source
w x20,21 .
2.5. Transglutaminase assay
Clone 1, clone 5 and clone Ser cells 80% conflu-
.ent were mechanically removed from their dishes,
washed three times with PBS, resuspended and ho-
mogenized following procedures previously de-
scribed. Transglutaminase activity was measured by
detecting the Ca2q-dependent incorporation of
w3 x  . H spermidine spd NEN Dupont, S.A.s15.6
. X  .Cirmmol into N, N -dimethylated casein DMC as
w xpreviously reported 9,10 . The incubation mixture
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 .contained 125 mM Tris-HCl pH 8.0 , 2.5 mM CaCl ,2
w3 x10 mM dithiothreitol, 200 mg DMC, 0.1 mM H spd
and 5–25 mg of protein from subcellular fractions
 .cytosolic and membrane-enriched in a final volume
of 0.1 ml. After 30 min of incubation at 378C, the
samples were precipitated with 10% TCA and free
w3 xH spd was eliminated by washing with large vol-
umes of cold 10% TCA containing 1 mM spd. The
w3 xpellet was finally resuspended and bound H spd
was counted with 5 ml of Pico Fluor 30 scintillation
 .cocktail United TechnologiesrPackard .
2.6. Adenylate cyclase isoforms RNA detection by
RT-PCR
 .  .Adenylate cyclase AC isoforms I–VIII total
RNA levels were detected by following a RT-PCR
w xprotocol previously described by Krupinski et al. 22
and modified as follows. Total RNA obtained from
 .clone 1, clone 5 and clone Ser cells densitys80%
by using a commercial kit InViSorb InViTeK, Ger-
. many , was reversely transcribed both by using oligo
.dT and random primers using the commercial kit
 .Superscript II Gibco BRL, Life Technologies . PCR
on the first strand of cDNA was carried out by
following the manufacturer’s protocol Boehringer
.Mannheim, Germany with 6.4 mM sense primer and
 .1.6 mM antisense primer 50 nM per degeneracy .
 XSense primers: 5 GGN GAY TGY TAY TAY TG
3X; Antisense primers: 5X CCA NAC RTC RWA YTG
.CCA . Degenerate positions in the sense primers
encode the amino acid sequence GDCYY and the
first two nucleotides of a final cysteine codon. The
antisense primers include the sequence complemen-
tary to the possible codons for the aminoacids
 .WQY F DVW. These amino acid sequences are iden-
w xtical among types I–VIII adenylate cyclase 22 and
their relative positions implied that the PCR product
synthesized would include 172 nucleotides from the
adenylate cyclase cDNA template flanked by the
primer sequences. As internal control, sense and anti-
sense primers to mouse glyceraldheyde 3X-phosphate
 .deydrogenase GAPDH gene were added to the PCR
assay mixture following the protocol described by the
PCR kit manufacturer Boehringer Mannheim, Ger-
.many . PCR products synthesized by using a sense
primer GGGCATCTTGGGCTACACTGAGGACC
and an antisense primer GGGGGCCGAGTT-
GGGATAGGG would include 262 nucleotides from
the GAPDH cDNA template flanked by the se-
quences. PCR protocol was performed as follows:
denaturation: 948C; annealing 528C, elongation 728C.
In order to obtain comparable levels between the
adenylate cyclase and GAPDH PCR products, primers
to GAPDH were added to the incubation mixture 10
cycles after the starting of the amplification protocol.
Aliquots from the PCR mixture assay were taken
 .after different cycle numbers 20, 28, 36 in which a
linear increase of the synthesized products could be
observed. PCR products were then separated on 1.5%
agarose gel and their relative intensities determined
 .by laser densitometry UltroScan XL, Pharmacia .
2.7. Adenylate cyclase assay
The adenylate cyclase assay was performed ac-
w xcording to a published procedure 21 . The reaction
mixture contained, in a final volume of 100 ml,
50–100 mg of membrane proteins as enzymatic
source. PT treatment for clone 1 and clone 5 cells
was carried out for 18 h before the assay. Mn2q and
forskolin were added to the incubation mixture as
adenylate cyclase modulators at the final concentra-
tion reported in the figures or tables. The adenylate
w32 xcyclase specific activity was expressed as P cAMP
formed per mg of membrane proteinsrmin. The c-
AMP was recovered from the reaction mixtures by
w xchromatographic procedures 23 .
2.8. Immunodetection of tissue transglutaminase and
a G-proteins
For tissue transglutaminase immunodetection,
clone 1, 5 and Ser cells and BAE cells control and
.pSG5-tTGase-AS transfected were washed three
times with PBS. Ten mg of protein from subcellular
 .fractions cytosol and membrane obtained as previ-
ously described, were subjected to SDS-PAGE using
w xa 10% polyacrylamide gel 25 . Proteins were then
electroblotted to type HA 0.45-mm pore nitrocellu-
 .lose paper Millipore Corp., Bedford, MA, USA .
The primary antibody, an affinity purified goat anti-
guinea pig liver tissue transglutaminase IgG, was
diluted 1 : 2000 with a blocking solution containing
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5% milk.
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The secondary antibody, rabbit anti-goat IgG anti-
serum conjugated with alkaline phosphatase Bio-Rad,
.Richmond, CA, USA was diluted 1 : 3000 with the
blocking solution previously described. Positive con-
trols were represented by purified guinea pig liver
 .tissue transglutaminase 2–5 ng of protein .
For the immunodetection of the a G-proteins, pro-
teins from membrane preparations were separated by
w x10% SDS-PAGE 24 , and transferred onto a nitro-
 .cellulose sheet Schleicher and Schuell . The anti-as
and the anti-a antibodies were purchased fromi
NEN-Du Pont. Goat anti-rabbit IgG, conjugated with
 .alkaline phosphatase BioRad were used as detection
system according to the manufacturer instructions.
Densitometric scanning of a i and a s immunoposi-
tive bands was carried out by using the program
 .Gel-Pro Analyzer Media Cybernetics, version 1.0.1 .
2.9. Protein concentration
The protein concentration was determined accord-
w xing to the procedure described by Bradford 25 .
3. Results and discussion
3.1. Transglutaminase acti˝ity in stably transfected
Balb-C 3T3 fibroblasts
Previous studies have reported that tissue transglu-
taminase is mostly recovered in the soluble fraction
of cell homogenates with a small fraction of the
enzyme detectable in the particulate components
w x26,27 . To determine the membrane-bound subcellu-
lar aliquot of the enzyme in the tTGase-transfected
w x  .Balb-C 3T3 fibroblasts 15 , clone 1 control , clone
 . 5 wild type tTGase-transfected and clone Ser ac-
.tive site mutated tTGase-transfected cells were ho-
mogenized and separated into cytosol and membrane
fractions by following a centrifugation procedure in-
tended to preserve cellular membranes from the loss
 .of the G-protein endowment see Section 2 . Tissue
transglutaminase activity was undetectable in both
clone 1 and clone Ser subcellular fractions, confirm-
ing that cysteine residue 277 is essential for the tissue
transglutaminase activity. The specific activities de-
termined in the cytosol and membrane fractions of
clone 5 were respectively 264.9 and 157.2 pmolr30
 .minrmg of protein Table 1 . The obtained results
demonstrate that in stably transfected Balb-C 3T3
cells a significant fraction of the enzymatic activity
 .more than 30% was recovered in the membrane
fraction.
3.2. Tissue transglutaminase immunodetection in sta-
bly transfected Balb-C 3T3 fibroblasts
To determine the tissue transglutaminase antigen
levels in cytosol and membrane fractions of clone 1,
5 and Ser cells, a Western blot analysis was carried
out by using an affinity purified goat anti-guinea pig
liver tissue transglutaminase IgG. No tissue transglu-
taminase antigen was detectable by this analysis limit
.of sensitivity: 2 ng of purified antigen in subcellular
fractions derived from clone 1. An immunoreactive
signal was detected in both subcellular fractions ob-
tained from clone 5 and clone Ser cells, that corre-
sponded with the comigrating purified antigen Fig.
.1 , although a slightly lower Mr for the tissue transg-
lutaminase in the membrane fractions was observed.
Table 1
 .Determination of transglutaminase specific activity in total homogenate and subcellular fractions from clone 1 control , clone 5
 .  .tTGase-transfected and clone Ser active site-mutated tTGase-transfected Balb-C 3T3 fibroblasts
Transglutaminase activity
 .pmol of spd incorporatedr30 minrmg of protein
clone 1 clone 5 clone Ser
Total homogenates N.D. 107.1"5.1 N.D.
Membranes N.D. 157.2"7.8 N.D.
Cytosols N.D. 264.9"12.5 N.D.
Values represent the means"S.D. of three different experiments. Further experimental details are reported in the text. N.D.snot
detectable.
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 .Fig. 1. Immunological detection Western blots of tissue transg-
lutaminase in cytosol and membrane fractions from clone 1
 .control , clone 5 and clone Ser cells. Ten micrograms of cytosol
 .  .lanes 1, 2 and 3 and membrane lanes 4, 5 and 6 fractions from
 .  .clone 1 control, lanes 1 and 4 , clone 5 lanes 2 and 5 and clone
 .Ser lanes 3 and 6 were fractionated on 10% SDS-PAGE,
transferred to nitrocellulose and probed with antisera raised
against guinea pig liver tissue transglutaminase. Further experi-
mental details are reported in the text.
With respect to the relative intensity of the im-
munoreactive signals present in the lanes correspond-
ing to cytosol and membrane fractions of clone 5
cells, we observed that the immunoreative signals
didn’t match the transglutaminase specific activity as
determined by enzymatic assays in the same frac-
tions. A possible explanation for such findings could
be that the enzyme localized in the membrane frac-
tion has reduced transglutaminase activity, likely due
to the presence of post-translational modifications
w x28 .
3.3. Adenylate cyclase acti˝ity in stably transfected
Balb-C 3T3 fibroblasts
The results reported in Table 2 indicate that the
basal adenylate cyclase activity in Balb-C 3T3 con-
 .trol cells clone 1 is under a dual reciprocal control
by a and a with a prevailing control exerted bys i
a . In fact, when both a and a control are removedi i s
Fig. 2. Adenylate cyclase activity in the membrane fractions of
 .clone 1 control , clone 5 and clone Ser cells. Adenylate cyclase
activity was determined by using 50–100 mg of membrane
proteins as enzymatic source after the addition of different con-
centrations of forskolin. The results are expressed as pmoles of
 .cAMPrminrmg of protein with S.D. less than 6% . Further
experimental are reported in the Section 2.
in the presence of Mn2q, the adenylate cyclase activ-
ity results substantially increased and it can be further
stimulated in the presence of forskolin Table 2 and
.Fig. 2 . The removal of the a control can be ob-i
tained in vivo by treating the cells with PT for 18 h
and the addition of forskolin in vitro to the mem-
branes prepared from the PT-treated cells can further
 .stimulate the adenylate cyclase activity Table 3 .
The adenylate cyclase activity in the clone 5 cells
 .tTGase-transfected in all the tested experimental
conditions is always more than 50% lower than the
activity in control cells. The results obtained showed
a stronger negative control on the adenylate cyclase
activity of the tTGase-transfected cells. Since this
effect could have been due to an unbalanced a ands
Table 2
 .  .  .Adenylate cyclase activity in clone 1 control , clone 5 tTGase-transfected and clone Ser active site-mutated tTGase-transfected
membranes
Addition Adenylate cyclase activity
 .pmol of synthesized cAMPrminrmg of protein
clone 1 clone 5 clone Ser
Basal 11.73"0.4 3.06"0.1 1.46"1
2q  .Mn 20 mM 24.80"0.6 7.40"0.2 9.60"0.3
2q  .  .Mn 20 mM and forskolin 10 mM 538.0 "13.5 118.0 "2.9 34.0 "1.8
Each value represents the mean"S.D. of three independent determinations performed in triplicate. Further experimental details are
reported in the text.
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Table 3
 .Adenylate cyclase activity in membranes from clone 1 control
 .and clone 5 tTGase-transfected treated with PT for 18 h before
the adenylate cyclase assay
Addition Adenylate cyclase activity
pmol of cAMP synthesizedr
.minrmg of protein
clone 1 clone 5
Basal 41.18"1.3 15.75"0.6
y5 .Forskolin 10 M 333.0 "11.1 205.38"7.8
Each value represents the mean"S.D. of three independent
determinations performed in triplicate. Further experimental de-
tails are reported in the text.
a control on the enzyme, we determined their con-i
centrations by an immunological assay. The data
shown in Fig. 3 clearly demonstrate that similar
concentrations of the two a G-proteins are present in
both clones suggesting that no clonal variations be-
tween the two clones have modified the endogenous
levels of these critical adenylate cyclase activity
modulators. Therefore it appears that the tissue trans-
glutaminase expression results in a negative control
on the adenylate cyclase enzyme, additive to but
independent from the control due to a . Moreover thei
results obtained in the presence of forskolin and
reported in Table 2 and Fig. 2, indicate that the
additive negative control cannot be removed either
 y6 .when lower concentrations 10 M allow a tos
Fig. 3. Western blot detection of a and a subunits, in clone 1s i
and clone 5 cell membranes. Fifteen micrograms of crude cell
membranes were fractionated on 10% SDS-PAGE, transferred to
nitrocellulose and probed with antisera raised against a or a .s i
Cl 1sclone 1; Cl 5sclone 5. a subunit relative area intensi-i
ties: Clone 1s88; clone 5s91.6. a subunit relative areas
intensities: clone 1s90.6; clone 5s91.3. Further experimental
details are reported in the Section 2.
interact with the enzyme, or when higher concentra-
 y4 .tions 10 M directly stimulate the enzyme. It
remains to be elucidated whether the negative control
exerted on the adenylate cyclase enzyme by the
overexpressed tissue transglutaminase is due to its
crosslinking activity or to its GTP bindingrhydrolyz-
ing activity. In fact, if from one hand we are aware
that the overexpressed tissue transglutaminase very
unlikely would find in the cells a Ca2q concentration
in the millimolar range, such as it is required for the
w xtransglutaminase crosslinking activity 10,11 , on the
w xother hand our previous results 29 demonstrated that
specific covalent modification of pigeon erithrocyte
membranes catalyzed by exogenous transglutaminase,
resulted in the inhibition of the adenylate cyclase
activity. To answer the question with a clear cut, we
looked at the adenylate cyclase activity of cells clone
.Ser transfected with a mutated tissue transglutami-
nase, in which the substitution of the cystein residue
277 with a serine in the active site of the enzyme,
results in a complete loss of the crosslinking activity
 .see Table 1 . The results obtained with clone Ser and
shown in Table 2 and in Fig. 2 confirm the exprimen-
tal findings obtained in clone 5 cells. In each of the
experimental conditions we tested, the adenylate cy-
clase activity detectable in the membranes of the wild
type and the active site mutated tissue transglutami-
nase transfected cells is always lower more than
.50% than in clone 1 control cells. Finally, a further
support to our conclusions was obtained by determin-
ing the adenylate cyclase RNA expression levels in
the three clones. In fact, to exclude the possibility
that the lower adenylate cyclase activity found in
clone 5 and Ser could be due to a reduced expression
 .of its gene s , we determined the RNA expression
level of eight isoforms described in the literature for
w xthis enzyme 22 . By using an RT-PCR protocol
optimized to identify adenylate cyclase isoforms I–
w xVIII 22 , no significant differences were observed
 .between the three clones Fig. 4 . These results, taken
all together, strongly suggest that tTGase represents a
negative modulator of the adenylate cyclase activity.
3.4. tTGase reduced expression is associated with an
increase of adenylate cyclase acti˝ity in BAE cells
The results described in the previous paragraph
showed an inverse correlation between the tTGase
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Fig. 4. Detection of adenylate cyclase RNA expression levels in
stably transfected Balb-C 3T3 fibroblasts clone 1, clone 5 and
.clone Ser . Total RNA extracted from 80% confluent cells was
reversely transcribed as described in Section 2. First strand
cDNA from each cell clone was subjected to a PCR assay and the
PCR products analyzed as described in the Section 2. Lanes 1, 2,
3: clone 1, clone 5 and clone Ser after 20 cycles. Lanes 4, 5, 6:
clone 1, clone 5 and clone Ser after 28 cycles. Adenylate cyclase
 .AC relative area intensities: 0.224; 0.232; 0.198. Glycerald-
X  .heyde 3 -phosphate deydrogenase GAPDH relative area intensi-
.ties: 0.264; 0.216; 0.201 .
expression and the adenylate cyclase activity in Balb-
C 3T3 fibroblasts. To confirm these findings and to
corroborate the effective physiological role of the
bifunctional tTGaserGa h protein on the adenylate
cyclase signaling pathway Balb-C 3T3 fibroblast do
.not express normally tissue transglutaminase , we
decided to use an alternative experimental model. In
particular, we expressed the eukaryotic expression
vector pSG5 containing the tTGase cDNA in anti-
sense orientation in BAE cells. This cellular model
appeared to us particularly suitable for our experi-
mental plans since, it basally expresses very high
w xtTGase levels 17 and show a low basal adenylate
cyclase activity. The transfection of BAE cells by a
lipofection technique with a pSG5 eukaryotic expres-
sion vector containing the tTGase cDNA in antisense
 .orientation pSG5-tTGase-AS was capable to reduce
the tTGase expression of almost 50% as determined
both by western blot or by enzymatic assay; Fig. 5
.and Table 4 in comparison with the cells transfected
 .with the vector pSG5 alone control . Conversely, a
dramatic increase of the adenylate cyclase activity
 .about 8 folds was determined in the membrane
fraction of the pSG5-tTGase-AS transfected cells
 .Table 4 . This finding, although obtained in the BAE
 .Fig. 5. tTGase immunodetection Western blotting in BAE cells.
Western blot analysis of cytosol and membrane fractions from
 .control and pSG5-tTGase-transfected cells 10 mg of each was
carried out as described in the Section 2. 1 and 3scytosol and
membrane fractions from control BAE cells; 2 and 4scytosol
and membrane fractions from BAE cells transfected with pSG5-
tTGase-AS expression vector.
cells which, in respect to Balb-C 3T3 fibroblasts,
could exert different molecular mechanisms in regu-
lating the adenylate cyclase signal transduction path-
way expression of specific adenylate cyclase iso-
.forms or different levels of a and a subunits ,i s
further supports the possibility that tTGase can play a
physiological role as a potent negative modulator of
the adenylate cyclase activity.
3.5. Concluding remarks
We have been interested in understanding the
physiological role of the tissue transglutaminase for
w xseveral years 15,29 . Many reports from several
investigators have recently shown that the tissue
transglutaminase, a calcium-dependent enzyme which
catalyzes the crosslinking of proteins and possesses
GTP binding and hydrolyzing activity, is capable to
mediate, at the membrane level, the a -adrenergic1
and the oxytocin receptor signals to phospholipase C
w x14,30,31 and associates with other proteins capable
w xto modulate its affinity to GTP 32 . In addition, Sing
w xet al. 33 recently reported the identification and the
characterization of an 80 Kd GTP-bindingrtrans-
glutaminase from rabbit liver nuclei suggesting that
Table 4
Transglutaminase and adenylate cyclase activities in membrane fractions from control and pSG5-tTGase-AS-transfected BAE cells
Transglutaminase activity Adenylate cyclase activity
 pmol of spd incorporatedr pmol of cAMP synthesizedr
. .30 minrmg of protein minrmg of protein
 .Control pSG5 alone 158.7"9.5 2.96"0.12
pSG5-tTGase-AS 65.4"7.2 24.11"2.8
Each value represents the mean"S.D. of two independent determinations performed in triplicate. Further experimental details are
reported in the text.
( )V. Gentile et al.rBiochimica et Biophysica Acta 1357 1997 115–122122
tissue transglutaminase might represent a new family
of GTP-binding proteins playing a critical role in
some cellular events, such as nuclear transport pro-
cesses and nuclear envelope organization. Therefore,
the findings obtained on the membranes obtained
both from stably transfected Balb-C 3T3 fibroblasts
and from the BAE cells transfected with pSG5-
tTGase-AS strongly support the possibility that the
tissue transglutaminase can play its physiological role
in vivo as a bifunctional tTGaserGa h protein, either
by strengthening the a control on the adenylatei
cyclase enzyme or by directly determining, like other
classical a G-proteins, a negative modulation on thei
adenylate cyclase. In this regard, the finding that a i
G-proteins may directly inhibit each adenylate cy-
w xclase isoform 34 , further supports the evidence for a
critical role of the tTGase as a bifunctional enzyme
whose physiological role is still not completely un-
derstood and may be exerted, at different levels, in
critical cellular events, such as cell growth and differ-
w x w xentiation 35 and apoptosis 36 .
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